Program
etentamig
Also written as “Etentamig”, “Etentamig (ABBV-383)” and “ABBV-383 (Etentamig)”.
In AbbVie's pipeline, CD3, BCMA
. Its studies are mostly in Multiple Myeloma · Amyloidosis, led by AbbVie.
Furthest: phase 3, since Nov 28, 202311 company-led studies, 11 open or runningNext primary completion: Feb 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 1111 open or running | phase 3since Nov 28, 2023 | Apr 26, 2019 | Feb 2027phase 1 · NCT06223516 |
- Named in AbbVie’s own pipeline as
Etentamig (ABBV-383)
, phase 4, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 26, 2019First study: phase 2 study in Multiple MyelomaFirst studyNCT03933735 · 220 enrolled · United States, Germany
- Mar 17, 2022Phase 1 study in Multiple MyelomaNCT05286229 · 8 enrolled · Japan
- Dec 6, 2022Phase 1 study in Multiple MyelomaNCT05650632 · 250 planned · United States, Canada, Denmark and more
- Nov 28, 2023Phase 2 study in AmyloidosisNCT06158854 · 76 planned · United States, Australia, France and more
- Nov 28, 2023Phase 3 study in Multiple MyelomaNCT06158841 · 421 enrolled · United States, Australia, Austria and more
- Jan 17, 2024Phase 1 study in Multiple MyelomaNCT06223516 · 60 enrolled · United States, Germany, Israel and more
- Mar 19, 2025Phase 1 study in Multiple MyelomaNCT06896916 · 135 planned · United States, Australia, Canada and more
- Mar 19, 2025Phase 2 study in Multiple MyelomaNCT06892522 · 602 planned · United States, Australia, Israel and more
- Jul 24, 2025Phase 3 study in Multiple MyelomaNCT07095452 · 680 planned · United States, France, Japan and more
- Jul 22, 2026Phase 3 study in RecurrenceNCT07728188 · 520 planned · United States, Australia, Canada and more
- Aug 26, 2026Phase 3 study in AmyloidosisNCT07793422 · 370 planned
- Oct 19, 2026Primary completion moved from 2040-09 to 2041-03Date moved laterphase 3 · +6 months · NCT07095452
Ahead
- Feb 2027Primary completion: phase 1 study in Multiple MyelomaNCT06223516
- Dec 2027Primary completion: phase 3 study in Multiple MyelomaNCT06158841
- Feb 2028Primary completion: phase 2 study in AmyloidosisNCT06158854
- Aug 2029Primary completion: phase 1 study in Multiple MyelomaNCT05650632
TargetBeta
“CD3, BCMA”the company's pipeline, read by Claude · source
“A T-cell engaging, human, bispecific, immunoglobulin G4 (IgG4) monoclonal antibody (T-BsAb) directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and CD3 antigen found on T-lymphocytes, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elranatamabrule | Pfizer | phase 4 | 15 |
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 13 |
| teclistamabrule | Johnson & Johnson | phase 4 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| cizutamigrule | UCB | phase 2 | 5 |
| vonsetamigrule | Regeneron Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rule | kelonia-therapeutics-inc | phase 1 | 1 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07793422Amyloidosis | 3 | Not yet recruiting | Dec 2034 | 370 |
| NCT07728188Recurrence · United States, Australia, Canada and more | 3 | Not yet recruiting | Feb 2033 | 520 |
| NCT07095452Multiple Myeloma · United States, France, Japan and more | 3 | Recruiting | Mar 2041 | 680 |
| NCT06896916Multiple Myeloma · United States, Australia, Canada and more | 1 | Recruiting | Mar 2036 | 135 |
| NCT06892522Multiple Myeloma · United States, Australia, Israel and more | 2 | Recruiting | Dec 2035 | 602 |
| NCT06223516Multiple Myeloma · United States, Germany, Israel and more | 1 | Active, not recruiting | Feb 2027 | 60 |
| NCT06158854Amyloidosis · United States, Australia, France and more | 2 | Recruiting | Feb 2028 | 76 |
| NCT06158841Multiple Myeloma · United States, Australia, Austria and more | 3 | Active, not recruiting | Dec 2027 | 421 |
| NCT05650632Multiple Myeloma · United States, Canada, Denmark and more | 1 | Recruiting | Aug 2029 | 250 |
| NCT05286229Multiple Myeloma · Japan | 1 | Active, not recruiting | Mar 2026 | 8 |
| NCT03933735Multiple Myeloma · United States, Germany | 2 | Active, not recruiting | May 2026 | 220 |
How it is read
Names in the registry
- “Etentamig”, 9 entries
- “Etentamig (ABBV-383)”, 1 entry
- “ABBV-383 (Etentamig)”, 1 entry
- “Subcutaneous (SC) Etentamig”, 1 entry
- “Intravenous (IV) Etentamig”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 9 studies
- Amyloidosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.